Interim Phase II study results showed than when paired with ribavirin, Locteron demonstrated potency against Hepatitis C similar to pegylated interferon. In addition, Locteron demonstrated 57 percent fewer adverse effects at a more favorable dosing schedule of once every other week.<\/p>\n
Biolex Announces Presentation at EASL of Interim Results From EMPOWER Phase 2b Study of Locteron\u00ae in Chronic Hepatitis C<\/p>\n
Locteron Dosed Once Every Two Weeks Demonstrated a Comparable Reduction in Viral Load Compared to Once-Weekly Standard of Care With 57% Less Flu-Like Adverse Events<\/p>\n
PITTSBORO, NC–(Marketwire – April 16, 2010) – Biolex Therapeutics, Inc. announced that interim results from EMPOWER, a prospectively designed analysis of results from two Phase 2b trials of Locteron\u00ae, were presented yesterday in a late-breaker session at the 45th Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria. Locteron, controlled-release interferon alpha 2b, is designed to improve patient care by providing a more convenient once-every-two week dosing schedule and by reducing the flu-like symptoms associated with pegylated interferons, the current standard of care. In the EMPOWER study, the 480 \u00b5g dose of Locteron demonstrated viral kinetics and response rates that were comparable to the PEG-Intron\u00ae control while also achieving a 57% reduction in flu-like adverse events. <\/p>\n